ASCO GI 2016: FOLFOXIRI Plus Bevacizumab in Colorectal Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
At the ASCO Genitourinary Cancers Symposium (ASCO GI 2016), researchers presented updated clinical data on the use of FOLFOXIRI chemotherapy in combination with Bevacizumab (Avastin) for the treatment of metastatic colorectal cancer.
Key Findings: FOLFOXIRI + Bevacizumab
The combination of FOLFOXIRI (a triplet regimen consisting of 5-FU, Leucovorin, Oxaliplatin, and Irinotecan) plus Bevacizumab has emerged as one of the most effective first-line treatment strategies for patients with metastatic colorectal cancer who can tolerate more intensive therapy.
Clinical Impact:
- Response Rates: The combination demonstrates high objective response rates, facilitating surgical resection of previously inoperable metastases in some patients.
- Survival Benefit: Clinical trials continue to show superior progression-free and overall survival outcomes with the triplet combination compared to standard doublet regimens (like FOLFOX or FOLFIRI) plus Bevacizumab.
Conclusion
The data from ASCO GI 2016 reinforce the role of FOLFOXIRI plus Bevacizumab as a standard-of-care option for fit patients with metastatic colorectal cancer, particularly those for whom maximal tumor shrinkage is a primary clinical goal.
Source: ASCO Meeting Library - FOLFOXIRI + Bevacizumab Results
#ColorectalCancer #FOLFOXIRI #Bevacizumab #Avastin #ASCOGI2016 #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4